<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753710</url>
  </required_header>
  <id_info>
    <org_study_id>CHL.3-02-2019</org_study_id>
    <nct_id>NCT04753710</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers</brief_title>
  <official_title>A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sintetica SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sintetica SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assess efficacy, safety and tolerability of Chloroprocaine 3% ophthalmic gel in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is carried out in 2 parts. In part I, safety and tolerability is assessed in three&#xD;
      groups (12 subjects per group) for single and multiple instillations (1 drop, 3 drops and 3+3&#xD;
      drops). In each group, 9 subjects is randomized to receive Chloroprocaine 3% Gel and 3&#xD;
      subjects receive vehicle as control in the right eye. After part I is completed, an internal&#xD;
      independent board review safety endpoints of data collected from these first subjects and&#xD;
      advise to go on with further enrollment.&#xD;
&#xD;
      If no safety concerns arise, in part II efficacy, safety and tolerability is assessed in 60&#xD;
      healthy subjects for the 3 drops dose regimen. 40 subjects receive Chloroprocaine 3% Gel and&#xD;
      20 receive vehicle (2:1 randomization) in the right eye.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Actual">December 9, 2020</completion_date>
  <primary_completion_date type="Actual">November 6, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>full anaesthesia of the ocular surface</measure>
    <time_frame>Day 1</time_frame>
    <description>Estimate the proportion of subjects experiencing full anaesthesia of the ocular surface 5 minutes after administration of Chloroprocaine 3% ophthalmic gel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of anesthesia</measure>
    <time_frame>Day 1</time_frame>
    <description>• Estimate time to anesthesia and duration of anesthesia, as well as Cochet Bonnet assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>• Assess the occurrence of:&#xD;
Ocular symptoms&#xD;
Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pressure and heart rate</measure>
    <time_frame>up to 8 days</time_frame>
    <description>• Blood pressure and heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>slit lamp examination</measure>
    <time_frame>up to 8 days</time_frame>
    <description>• Slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corneal fluorescein staining</measure>
    <time_frame>up to 8 days</time_frame>
    <description>• Corneal fluorescein staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ocular pressure</measure>
    <time_frame>up to 8 days</time_frame>
    <description>• Intraocular pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Chloroprocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroprocaine 3% ocular gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle for chloroprocaine 3% ocular gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocular gel</intervention_name>
    <description>Instillation</description>
    <arm_group_label>Chloroprocaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent&#xD;
&#xD;
          2. Healthy male or female aged from 18 to 90 years&#xD;
&#xD;
          3. No clinically significant ocular or systemic disease&#xD;
&#xD;
          4. Ability to orally respond to pain&#xD;
&#xD;
          5. Ability to follow the visit schedule&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic exclusion criteria&#xD;
&#xD;
          1. Eye movement disorder (i.e. Nystagmus)&#xD;
&#xD;
          2. Dacryocystitis and all other pathologies of tears drainage system&#xD;
&#xD;
          3. History of Inflammatory ocular disease (Iritis, uveitis, herpetic keratitis)&#xD;
&#xD;
          4. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease&#xD;
             (including corneal ulceration and superficial punctuate keratitis)&#xD;
&#xD;
          5. History of ocular traumatism, infection or inflammation within the last 3 months&#xD;
&#xD;
          6. Best corrected visual acuity &lt; 1/10&#xD;
&#xD;
          7. History of ophthalmic surgical complication (i.e. cystoid macular oedema)&#xD;
&#xD;
             Systemic/non ophthalmic exclusion criteria&#xD;
&#xD;
          8. General history:&#xD;
&#xD;
             8.1 Deafness 8.2 Excessive anxiety&#xD;
&#xD;
          9. Any other medical or surgical history, disorder or disease such as acute or chronic&#xD;
             severe organic disease: hepatic, endocrine neoplastic, haematological diseases, severe&#xD;
             psychiatric illness, relevant cardiovascular abnormalities (such as unstable angina,&#xD;
             uncontrolled hypertension: systolic blood pressure over 200 mm Hg, diastolic blood&#xD;
             pressure over 100 mm Hg) and/or any complicating factor or structural abnormality&#xD;
             judged by the investigator to be incompatible with the study&#xD;
&#xD;
         10. Allergic history: Known hypersensitivity to one of the components of the study&#xD;
             medications or to test products&#xD;
&#xD;
             Specific non-inclusion criteria for women:&#xD;
&#xD;
         11. Pregnancy, lactation&#xD;
&#xD;
         12. Women without an effective method of contraception (i.e. oral contraceptive,&#xD;
             intra-uterine device, subcutaneous contraceptive implant) OR&#xD;
&#xD;
         13. Women not hysterectomised, not menopausal nor surgically sterilized&#xD;
&#xD;
             Exclusion criteria related to general conditions:&#xD;
&#xD;
         14. Inability of subject to understand the study procedures and thus inability to give&#xD;
             informed consent&#xD;
&#xD;
         15. Non-compliant subject (e.g. not willing to attend the follow-up visits, way of life&#xD;
             interfering with compliance)&#xD;
&#xD;
         16. Participation in another clinical study&#xD;
&#xD;
         17. Already included once in this study&#xD;
&#xD;
         18. Ward of court&#xD;
&#xD;
         19. Subject not covered by the Social Security&#xD;
&#xD;
             Exclusion criteria related to previous and concomitant medications (taken within 15&#xD;
             days prior screening visit)&#xD;
&#xD;
         20. Use of systemic opioids and opioid drugs&#xD;
&#xD;
         21. Topical ocular treatment with anaesthetic action&#xD;
&#xD;
         22. Use of systemic analgesic drugs (except paracetamol, which will be allowed after Visit&#xD;
             2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhoefer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinik für Klinische Pharmakologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>October 12, 2021</submitted>
    <returned>November 8, 2021</returned>
    <submitted>November 16, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

